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or at least a decent surrogate of it. A last methodological aspect of 
the problem concerns quality assessment, which is not uniform across 
studies, ranging from mild volumetric comparisons to stricter overlap 
indices, or even false positive/negative rates. The combination of all 
these methodological issues, with varying severity from publication to 
publication, makes any comparison or general comparison quite 
hazardous. 
With PET being now quite widely used in radiotherapy, these 
methodological issues cannot be longer overlooked and some groups 
are starting to tackle them. A first effort in this direction has been 
the work conducted together by the ESTRO and EANM, leading to joint 
sessions in their respective congresses and the publication of a special 
issue of Radiotherapy and Oncology. More recently, the AAPM has set 
up task group 211, which aims at gathering data from various sources, 
at clarifying quality assessment, at surveying the literature, and 
categorizing existing methods. Ultimately, this would allow a 
benchmarking tool to be built and made publicly available. This tool 
could also constitute a basis for training users and researchers in the 
domain, with hopefully the development of improved segmentation 
methods at the end of the road. Eventually, from the viewpoint of 
hardware and software, one can expect vendors to address directly 
the problem of segmentation, if not by the integration of 
segmentation tools, then at least by providing dedicated 
reconstruction algorithms and protocols. Any gain in spatial resolution 
or artifact reduction would indeed ease the difficulty of target 
delineation. 
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When young scientists begin their career, they will usually be given a 
project from their supervisor.Initially, they will probably know little 
about the subject or the project but as they begin working and gain 
knowledge, they should start to evaluate it and continue this 
evaluation regularly. This includes the importance of the goals,the 
feasibility of achieving them in the project time, whether the 
approach is optimum one and whether the relevant equipment and 
facilities are available.This is helped by having a good infrastructure 
such that each young scientist has a supervisory committee which 
should meet regularly (e.g. once a year) to evaluate progress of the 
scientist and the project. Specific and general problems can then be 
addressed and the project modified if necessary. If there is not 
already such an infrastructure in place, the scientist should been 
encouraged to press for one to be set up. 
It is also important, especially at the beginning of a scientific career, 
to meet with your direct supervisor frequently, e.g. once per week, to 
discuss you results, approaches to problems,plans, and to maintain 
focus. It is easy to get sidetracked into investigating interesting 
aspects but which are not directly relevant to the primary goals of the 
project. Keeping focus on the main goal will help shorten the time to 
publishing your first paper (an important milestone), getting your PhD, 
and hone your ability to continually to assess what is most important 
to you and your current project. 
Projects can be fundamental or translational, and both are valuable. 
The choice will depend on the interest and motivation of the scientist, 
e.g. does the scientist have a medical background or interest,is the 
primary purpose to improve cancer treatment, or is it to understand 
the response of cells or tissues to various stimuli including the 
different forms of treatment used for cancer (drugs, radiation, 
immunotherapy, anti-vascular approaches, etc)? If you don’t like 
working with animals, for example, make sure your project doesn’t 
demand their use. If you don’t want to study at the hard-core 
molecular biological level, for example, stick to the cultured cell, 
tissue or animal levels.  
Your time will be spent in, firstly, carrying out experiments to 
generate data, and secondly, in the continuous effort to increase your 
knowledge. Although focusing on your goals when planning 
experiments is highly recommended, it is equally important to read 
not just in your subject but around it, increasing your knowledge of 
general cancer biology, molecular biology, and cancer treatments. It 
is recommended to read not just abstracts, not just reviews, but also 
read the directly relevant papers in all their detail. This should also 
develop your critical faculties (is it new? are the data good? do you 
believe their conclusions? if not why not? have they used the best 
approaches? have they used the most optimum methods? etc). It can 
be also very helpful to discuss interesting papers with your 
colleagues,e.g in a literature club format. With regard to your general 
education, it is important and highly recommended to go to scientific 
seminars even if they are not on your specialist subject. Talks from 
some world experts are also available on the web (e.g. from the 
annual AACR meeting) which are often clear,stimulating and of high 
quality, and of course available to everyone wherever you work. 
Further advice is not to work in isolation. However good you are, you 
are likely to benefit from talking and/or working with others. At the 
very least, talk science to your colleagues regularly. Discussions with 
colleagues and attending regular scientific seminars are relatively 
easy in large academic institutes. If this doesn’t apply to you, it is 
recommended to set up collaborations with other groups working on 
similar subjects in other institutes. You are likely to benefit from their 
experience and vice versa, to progress more rapidly in your research, 
and be more competitive.  
Lastly, in terms of your career, you should assess your own 
performance and desires, particularly after three or four years in 
research. Are you naturally curious? Are you good at it? Are you 
enjoying it? Do new findings excite you? Do you come up with ideas (in 
addition to those of your supervisor’s)? Would you make a good group 
leader (supervising a lab with younger scientists, technicians, etc 
under you)? If yes, go for it! If not, it is advised to consider the many 
other possible non-research careers that would take advantage of your 
expertise, including in scientific publishing, various roles in 
pharmaceutical companies, etc. If you are unsure about your ability to 
lead others, to get experience you could try and persuade your 
supervisor to employ a younger student to work for you (e.g. for a 
number of months), or have a technician assigned to you. This can 
provide valuable experience whether or not you remain in a pure 
research position. 
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Intraoperative radiotherapy (IORT) and other recent developments in 
radiotherapy such as stereotactic radiosurgery (SRS), high-dose rate 
(HDR) brachytherapy boost, and stereotactic body radiotherapy (SBRT) 
apply a single or very few, very large fractions of radiation. This 
represents a major departure from conventional, fractionated 
radiotherapy and may produce different biological effects than 
predicted from multiple fractions of 1.8-2 Gy per day. Conventional 
radiotherapy is based on the relative sparing of late reacting normal 
tissue relative to the tumour achieved by giving the total dose in 
multiple fractions.However, irradiation with as few as 1-3 fractions 
has been surprisingly effective with acceptable normal-tissue reaction 
in various clinical settings. In this lecture, a review of various clinical 
and biological factors that may influence the therapeutic efficacy of 
single-dose irradiation will be given. Usually the target for single-dose 
IORT will be residual tumour foci in the tumour bed after excision of 
the tumour. The limited number of tumour cells will affect the dose 
response relative to solid tumours and the volume effect will help 
spare the normal tissue if the volume receiving a high dose is kept 
small. A frequent question is whether the linear-quadratic (L-Q) 
model is valid for comparing is offective doses of single-dose and 
conventionally fractionated radiotherapy. Although it can be argued 
that the L-Q model may not be theoretically exact for comparing the 
biological effect of single-dose with fractionated irradiation, clinical 
values of the essential parameter alpha/beta have wide confidence 
intervals which preclude inferences about the validity of the model. 
Nevertheless, the L-Q model remains useful as a first approximation. 
50 kV X-rays used in some applications of IORT have an increased RBE 
which must be taken into account when comparing effects with MV X-
rays. We have modelled the RBE by the L-Q formalism including 
effects of dose per fraction and dose rate for protracted irradiation 
and validated this by experimental measurements of RBE for cell 
inactivation after irradiation in a tumour-bed phantom. Various 
aspects of the cellular response to large doses of radiation may 
influence cell survival with threshold values most likely in the range 8-
15 Gy. Thus experimental evidence will be presented supporting the 
idea that the repair system responds differently to high single doses 
and that a cohort effect may add to the efficacy. The influence of the 
stroma and the micromilieu will be reviewed and the evidence for a 
role of immunological effects will be discussed.  
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 In conclusion, the conventional model of cell inactivation based on in 
vitro survival curves which can be described by the L-Q formalism is 
being complemented by complex mechanisms involving the cellular 
radiation response, interaction with other target cells, and the 
influence of the microenvironment and systemic factors. 
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Background: In 2010, we reported data on local control and early 
toxicity for theTARGIT-A trial of intraoperative radiotherapy after 
lumpectomy for early breastcancer (n = 2232, Vaidya et al, Lancet). 
Randomisation continued until a totalnumber of 3451 patients were 
included in June 2012. We present the updatedresults on local control 
and the first analysis of survival of the wholecohort. 
Methods: TARGIT-A was a randomised trial in patients >=45 years with 
invasive ductal carcinoma undergoing breast conserving surgery 
comparing standard fractionated whole breast EBRT (3-6 weeks) with 
single dose TARGIT (20 Gy)either given at the time of the primary 
operation (prepathology stratum) or ina delayed second procedure 
(post pathology stratum). The experimental arm mandated additional 
EBRT excluding a boost, if adverse features were detected on final 
pathology making this a “risk-adapted policy”. 3451, 2020 and 1222 
patients have a median follow-up of 2.5, 4 and 5 years, respectively. 
The primary outcome was ipsilateral within breast recurrence (IBR) 
with an absolute non-inferiority margin of 2.5% at 5 years and 
secondary outcome was survival. 
Results: 1721 patients were randomly allocated to receive TARGIT and 
1730 to EBRT. Primary events have increased from 13 to 34 since2010. 
For the primary outcome of ipsilateral breast recurrence, the absolute 
difference at 5-years was 2.0% (3.3% vs. 1.3%), which was higher with 
TARGIT; in prepathology the absolute difference in 5-year IBR was 1%; 
in post pathology it was 3.7%. For the secondary outcome, there was a 
non-significant trend for improved overall survival with TARGIT (HR = 
0.70) due to fewer non-breast cancer deaths (17 vs. 35, HR 0.47). 
Conclusion: Patients in the TARGIT-A trial have excellent 5 year 
outcomes (local control > 96%, overall survival >= 94%) in both arms of 
the trial. 
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Background: To assess the role of an intraoperative electron boost 
(IOERT) in combination with hypofractionated whole breast irradiation 
(WBI) in terms of in-breast tumor control and cosmeticoutcome. 
Methods: Starting in Jan 2011, a prospective multi-center single arm 
trial is conducted by the ISIORT. Patients receive an IOERT boost of 10 
Gy ( Dmax 11.1 Gy) followed by a WBI of 40.5 Gy in 15 fractions (2.7 
Gy single dose). 5-year in-breast-recurrence rates will be analyzed in 
3 different age groups (35–40y, 41-50y, >50y) and tested against the 
respective best published results from randomized prospective trials 
by the use of a sequential probability ratio test (SPRT). Acute 
reactions are assessed by CTC-scoring, late reactions according to 
LENT-SOMA criteria. Cosmesis is evaluated by a 5-point-Scoring System 
(van Limbergen, double evaluation) starting prior to WBI on the basis 
of repeated photodocumentation in standardized positions. 
Results: As of Jan2013, within six active institutions 327 patients have 
been recruited, 204 of them already in follow-up. Patient and tumor 
characteristics are summarized in Table 1.  
  
  
For IOERT, the median energy chosen was 6 MeV(range 4-12) with 
median tube diameters of 6 cm (3-8) and mean prescription depths of 
20 mm (13.8 SD), resulting in mean D90 volumes of 37 ml.  
Perioperatively, no major complications were observed. Four weeks 
after the end of WBI, 60 patients (29.8%) showed no reactions (CTC 0), 
130 patients (66.2%) presented with faint (CTC 1) and eight (4%) with 
moderate to brisk erythema (CTC 2),respectively. Four to five months 
after the end of treatment, late reactions according to LENT-SOMA 
criteria were assessed in 159 patients, all of them scored as grade 0. 
At one year post WBI, 74 patients still presented as grade 0, one 
patient as grade 1. 
Cosmesis was assessed postoperatively in 217 patients, 159 were 
evaluated 4-5 months and 75 one year after the end of WBI, 
respectively. Baseline appearance prior toWBI was scored as excellent 
(E0) in 31.8/17.5% (patients/doctors), good (E1) in 52/50.4%, 
moderate (E2) in 14.3/27.6%, bad (E3) in 1.4/4.5% and complication 
(E4) in 0.5/0%.  At 4 months post RT, there was a trend towards 
better rating:  E0: 34.6/21.3%; E1: 51.6/46.9%; E2: 12.6/27.3%,E 3: 
1.2/4.5%.  Results at 12 months follow-up were similar. 
At a median follow-up period of 12 months (3-16), no recurrence was 
noted. 
Conclusion: Tolerance of a combined IOERT / hypofractionated WBI 
regimen is excellent, acute reactions moderate and late reactions 
insignificant in short-term assessment. With regard to postoperative 
appearance, early cosmetic results are not impaired. Both tumor 
control and cosmetic outcome have to be evaluated on long-term 
follow-up. 
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